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Abstract
Pneumococcal meningitis is the most common and severe form of bacterial meningitis. Fatality rates are
substantial, and long-term sequelae develop in about half of survivors. Here, we have performed a prospective
nationwide genetic association study using the Human Exome BeadChip and identified gene variants in encoding
dynactin 4 (DCTN4), retinoic acid early transcript 1E (RAET1E), and V-akt murine thymoma viral oncogene homolog 3
(AKT3) to be associated with unfavourable outcome in patients with pneumococcal meningitis. No clinical replication
cohort is available, so we validated the role of one of these targets, AKT3, in a pneumococcal meningitis mouse model.
Akt3 deficient mice had worse survival and increased histopathology scores for parenchymal damage (infiltration) and
vascular infiltration (large meningeal artery inflammation) but similar bacterial loads, cytokine responses, compared to
wild-type mice. We found no differences in cerebrospinal fluid cytokine levels between patients with risk or non-risk
alleles. Patients with the risk genotype (rs10157763, AA) presented with low scores on the Glasgow Coma Scale and
high rate of epileptic seizures. Thus, our results show that AKT3 influences outcome of pneumococcal meningitis.
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Introduction
Bacterial meningitis is a severe infection of the central
nervous system, which is caused by Streptococcus pneu-
moniae in 70 % of cases [1]. Patients with pneumococcal
meningitis are at high risk for complications, such as
epileptic seizures and cerebral infarction, resulting in a
high mortality rates, and neurologic sequelae, including
hearing loss, focal neurological deficit, and cognitive im-
pairment, in almost half of survivors [2–7]. Following
the introduction of adjunctive dexamethasone treatment
the mortality rate of pneumococcal meningitis has de-
creased from 30 to 20 % [8–10], but new treatments are
urgently needed [11–13]. Interindividual differences in
severity of disease and outcome may be determined by
host genetic variation [14, 15]. So far, genetic association
studies in pneumococcal meningitis have used a candidate
gene approach in which variations in genes of interest
were studied [15–17], focusing on genes in the immune
system, for example the toll-like receptor signalling cas-
cade and the complement system [14, 15].
Whole-genome association studies, using an unbiased
approach, may identify new candidate genes and patho-
physiological mechanisms leading to an unfavourable out-
come in pneumococcal meningitis [17]. Such studies
should be performed prospectively, using a clear definition
of cases with microbiological confirmation, and validated
outcome scales [18]. In 2006, we started a nationwide
prospective cohort study to identify and characterize host
genetic traits and bacterial genetic factors controlling
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occurrence and outcome of bacterial meningitis (Menin-
Gene) [9, 18]. Here, we report our genome wide associ-
ation study on the host side, analysing the associations
between human genome variants and functional outcome
in patients with pneumococcal meningitis using the Hu-
man Exome BeadChip. We subsequently validated the role
of one of the top hits, AKT3, in a pneumococcal meningi-
tis mouse model. Finally, we studied whether patients with
the associated AKT3 rs10157763 risk allele had specific
clinical characteristics or cerebrospinal fluid (CSF) inflam-
matory marker profiles.
Materials and methods
Dutch bacterial meningitis cohort
In a nationwide prospective cohort study (MeninGene) we
included patients with community-acquired bacterial
meningitis with an age of 16 years or older with positive
CSF cultures who were identified by The Netherlands Ref-
erence Laboratory for Bacterial Meningitis (NRLBM) from
March 2006 to October 2011 [14]. The NRLBM receives
bacterial isolates from approximately 85 % of bacterial
meningitis patients in the Netherlands and provided the
names of the hospitals where patients with bacterial men-
ingitis had been admitted in the previous 2–6 days. Physi-
cians of the hospitals were contacted after which the
treating physician obtained informed consent from the pa-
tient or their legal representative. Online case record
forms were collected through a secured website and in-
cluded data on symptoms during the hospitalized period,
treatment, complications and outcome. Patients with
hospital-acquired bacterial meningitis and negative CSF
cultures were excluded. Outcome was graded at discharge
according to the Glasgow Outcome Scale (GOS), a well
validated instrument with good inter-observer agreement
[19]. On this five-point scale a score of 1 indicates death,
2 a vegetative state, 3 severe disability, 4 moderate disabil-
ity, and a score of 5 mild or no disability.
Blood for DNA extraction was collected in sodium/
EDTA tubes and DNA-isolation was performed with the
Gentra Puregene isolation kit (Qiagen) according to
manufacturer’s protocol thereafter the yield and quality
of the extractions were determined to ensure appropriate
conditions for genotyping.
Genotyping and quality control
Patients were genotyped on the Illumina HumanExome
BeadChip v1.1 consisting of >24,0000 markers, with
approximately 75 % of these markers having a minor al-
lele frequency (MAF) < 0.05. The genotyping was carried
out in collaboration with the Human Genome Facility
and the department of Epidemiology, Erasmus MC, the
Netherlands as part of the Netherlands ExomeChip Pro-
ject. After genotyping we performed genotype-calling on
all our MeninGene samples (N = 1322) to improve calling
accuracy and all non-pneumococcal meningitis patients
were removed after quality control (QC). All autosomal
SNPs were called using GenomeStudio software, from
Illumina, with the GenTrain2.0 cluster algorithm using
the protocol as described before [20].
Called data was exported in PLINK format for final
sample and SNP QC [21]. All samples with > 5 % missing
genotypes were removed. High quality, independent SNPs
with less than 1 % missing-genotypes, non-significant dif-
ferences between cases and controls with respect to rate
of missing genotypes, MAF >5 % and Hardy-Weinberg
equilibrium (HWE) p-value > 1 × 10−3 were used to deter-
mine relatedness between patients, heterozygosity and
ancestry. Individuals with second degree, or higher degree
relatedness, heterozygosity above or below three standard
deviations and non-European decent were left out. Finally
QC was performed by removing all SNPs with >5 % miss-
ing genotypes and HWE p-value < 1 × 10−6.
Mice
8- to 12-week-old male C57BL/6 N mice were obtained
from Charles River, whereas Akt3 -/- mice (backcrossed at
least 10 times to a C57BL/6 N background), generated as
described elsewhere [22] were bred and maintained at the
animal facility at the Academic Medical Center of
Amsterdam. The mice were kept to a controlled 12 h light/
dark cycle and food and water were provided ad libitum.
Experimental pneumococcal meningitis model
Pneumococcal meningitis was induced by intracisternal
inoculation with S. pneumoniae (serotype 3, American
Type Culture Collection #6303) as described previously
[18, 23–25]. In brief, wild-type and Akt3-/- mice (n = 12
per group) were randomly and blind inoculated with
1 μl bacterial suspension containing 1 × 104 CFU S.
pneumoniae into the cisterna magna under Isofluran
(Baxter) anaesthesia. Six mice per group inoculated with
sterile saline (Baxter) were used as controls. Cultures
were adjusted such that each final 1 μl inoculum con-
tained 1 × 104 CFU. Immediately after intracisternal in-
oculation, mice were assessed for neurologic damage as
a result of the puncture. No mice suffered from neuro-
logical damage as a result of puncture and had to be ex-
cluded. Mice were observed during 48 h post infection
and clinical signs of meningitis were blindly scored every
four hours as previously described [23]. In brief, the max-
imum score was determined by the estimated contribution
of the variable to overall health of the mouse: weight loss
(0–4 points), activity (0–4 points), time to return to up-
right position (0–6 points), state of skin/fur (0–3 points),
posture (0–2 points), eye discharge or protrusion (0–4
points), respiration rate (0–4 points), irregular/labored
breathing (0–4 points), epilepsy, limb paresis or ataxia (0–
10 points). Animals reaching endpoint criteria were
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humanely killed. In another set of experiments, at 6, 24 and
30 h post infection, 12 mice/group were anesthetized by in-
traperitoneal injection of 190 mg/kg ketamine (Eurovet
Animal Health) and 0.3 mg/kg dexmedetomidine (Pfizer
Animal Health) followed by cardiac puncture for blood col-
lection and perfusion of organs with sterile isotonic saline
via the left ventricle. CSF was collected by puncture of the
cisterna magna. Brain, lung and spleen were harvested,
placed on ice, processed and stored as described before
[23]. EDTA blood was centrifuged at 2000 × g for 15 min.
Plasma was stored at −80 °C for further analysis.
Real-time PCR
Total RNA was extracted from murine brain homoge-
nates using TriPure reagent (Sigma-Aldrich). The purity
of the RNA was assessed by the ratio of absorbance at
260 and 280 nm. RNA purity was within a range of 2.0–
2.1. RNA was stored in aliquots at −80 °C until used for
reverse transcription. For complementary DNA (cDNA)
synthesis, RNA was treated with RQ1 RNase-free DNase
(Promega) and reverse transcribed with SuperScript II
Reverse Transcriptase and random hexamers (Life Tech-
nologies). The real-time polymerase chain reaction (RT-
PCR) measurement of individual cDNAs was performed
on a Bio-Rad MyiQ Single-Color RT-PCR Detection Sys-
tem using the Bio-Rad iQ SYBR Green Supermix (Bio-Rad
Laboratories). The Non-POU-domain containing octamer
binding protein (nono, housekeeping gene) primers were
described previously [26]. Akt3 cDNA was amplified with
a forward 5′-CATCTGAAACAGACACCCGATA-3′ and
a reverse 5′-GTCCGCTTGCAGAGTAGGAG-3′ primer
for mouse akt3. Dctn4 cDNA was amplified with a for-
ward 5′- CACCCATGTGACTGTGTTGG and a reverse
5′-TGAAGATGCCCACTTTGTTG primer for a mouse
dctn4. Raet1E was amplified with a forward 5′-GGATA
CACCAACGGGCTG and a reverse 5′-GTCACACC
CAGGGAAGGTC primer for a mouse raet1e (all Applied
Biosystems). A negative control without the Reverse Tran-
scriptase was also used. The expression data were normal-
ized to the nono reference gene. Data were analyzed using
the Bio-Rad MyiQ Optical system Software version 1.0.
Murine histopathology and immunohistochemistry
Histopathology was performed on the right cerebral hemi-
sphere fixed in 4 % paraformaldehyde and paraffin embed-
ded. Coronal 5 μm sections of the right hemisphere were
cut for subsequent staining with hematoxylin and eosin
(HE) according to standard procedures. HE staining were
performed to visualize meningeal infiltration, parenchymal
damage, vascular inflammation, thrombosis and ventricu-
litis on a three point scale (Additional file 1). Sections of
mice 24 h after induction of pneumococcal meningitis
(n = 12 per group) were scored. Tissue sections were
stained for Caspase-3 using immunohistochemical
procedures in order to assess hippocampal apoptosis, as
described previously [24].
Determination of cytokines and chemokines
The murine cytokines interleukin (IL)-1β, IL-6, IL-10
and tumour-necrosis factor-α (TNF-α) and the chemo-
kines keratinocyte chemoattractant (KC) and macrophage
inflammatory protein (MIP)-2 were determined in plasma
and brain homogenates by Luminex technology using a
mouse Bioplex kit (Bio-Rad Laboratories) as described be-
fore [25]. The human cytokines IL-1β, IL-6, IL-10 and
TNF-α were determined in CSF collected from the diag-
nostic lumbar puncture. CSF samples were centrifuged
and supernatant was aliquoted and stored at −80 °C until
analysis. All analytes were measured with Luminex®
xMAP® technology using Milliplex® map multiplex assay’s
(Millipore Billerica). CSF was diluted 1:50 in assay buffer
provided with the Multiplex assay and inflammatory me-
diators were measured according to the manufacturer’s
instructions. CSF was available in 271 of the 689 (39 %) of
pneumococcal meningitis patients.
Statistics
All patients with pneumococcal meningitis were included
in the genetic association analysis for meningitis disease
severity/outcome. Severity/outcome was determined by
grouping patients on their GOS score where score 1 until
4 together was labelled unfavourable and score 5 as
favourable outcome. All calculations have been conducted
using PLINK 1.9 [27]. Differences between favourable and
unfavourable outcome were calculated using the Fisher’s
exact test on allelic association. For the genetic association
study, based on 321 patients with a favourable outcome
and 152 with unfavourable outcome, for 240,000 variants
and a MAF of 0.25, we had 80 % power to detect variants
with a OR of 3.4 or higher after Bonferroni correction.
Cytokine level differences between genotypes were com-
pared using a Mann-Whitney U test.
We used a multivariable logistic regression analysis to
calculate OR and 95 % CI to assess the strength of the asso-
ciation among potential risk factors (including identified
polymorphisms) and outcome. Murine gene expression,
bacterial load and inflammatory response data were com-
pared using Mann-Whitney U tests. Survival curves were
compared using a log rank test and clinical scores were
compared using a linear mixed model assuming an expo-
nential and group specific time effect. For all analyses, SPSS
(version 22) was used; differences were considered statisti-
cally significant at P < 0.05.
Results
Nationwide prospective cohort study
In a prospective nationwide study we included 1005
episodes of culture-proven community-acquired bacterial
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meningitis in 993 patients. The distribution of causative
bacteria was S. pneumoniae in 720 (72 %), Neisseria menin-
gitidis in 105 (11 %), and other bacteria in 180 (18 %)
episodes. DNA samples were obtained from 472 pneumo-
coccal meningitis patients (66 %) of whom 430 were from
Caucasian population (91 %). The mean age of pneumococ-
cal meningitis patients for whom DNA was available was
58 years and 221 (47 %) were male (Table 1). Predisposing
conditions, most commonly otitis or sinusitis (218 episodes,
46 %) or an immunocompromised state (124 episodes,
26 %) were present in 322 episodes (68 %). Upon presenta-
tion epileptic seizures occurred in 33 patients (7 %). During
clinical course, new focal neurologic deficits developed in
24 % of patients. Outcome was prospectively evaluated
using a validated outcome scale [19], the GOS, a score of 1
to 4 was defined as unfavourable outcome, a score 5 as
favourable outcome), in all 472 patients with pneumococcal
meningitis with DNA available: 151 (32 %) patients had an
unfavourable outcome and 37 (8 %) died.
Genetic association study
A total of 472 patients with pneumococcal meningitis were
genotyped on the Illumina Human Exome BeadChip. Of
the top five candidate single nucleotide polymorphisms
(SNPs) associated with unfavourable outcome (Table 2) two
pairs of candidate SNPs were in linkage disequilibrium (LD),
the rs11954652 and rs6869603 within the DCTN4 gene
(odds ratio [OR] 5.6 for unfavourable outcome, 95 % confi-
dence interval [CI] 2.4–12.9, p = 2.4× 10−5). Rs11954652 is a
missense variant and rs6869603 is a variant within a regula-
tory element before the DCTN4 gene. SNPs rs3798763 and
rs6925151 are also in LD and lay within the RAET1E gene
(OR 1.9 for unfavourable outcome, 95 % CI 1.4–2.6,
p=9.4× 10−5). Rs3798763 is an intron variant and rs6925151
is missense variant. Rs10157763 is located within the intron
of the AKT3 gene (OR 1.88 for unfavourable outcome, 95 %
CI 1.4–2.6, p= 9.9× 10−5). The missense variations within
DCTN4 and RAET1E had no predicted impact of amino
acid substitution on structure or function of the gene using
PolyPhen-2 [28]. The potential effect of other three varia-
tions on the protein structure or function was unclear.
Role of akt3 in the pneumococcal meningitis mouse model
To explore the role of AKT3, DCTN4, and RAET1E dur-
ing pneumococcal meningitis we determined their brain
expression levels in our mouse model [23]. Mice infected
intracisternally with 104 CFUs S. pneumoniae ATCC 6303,
had low akt3 mRNA expression in uninfected brain,
which decreased 30 h post-infection; dctn4 brain tran-
script levels of mice showed no increase after infection
(Fig. 1a). No raet1e product was detected. Subsequently,
we evaluated the functional role of Akt3 in pneumococcal
meningitis in our mouse model using knock-out mice. In
a randomized investigator-blinded study, Akt3 -/- mice
died faster than wild-type mice when incisternally infected
with 104 CFUs of S. pneumoniae ATCC 6303 (p = 0.036;
Fig. 1b). Disease severity scores were also higher in Akt3-/-
mice than wild-type mice (p = 0.002; Fig. 1c). The higher
Table 1 Clinical characteristics of 472 patients with community-acquired pneumococcal meningitisa
Characteristic Characteristic
Age – yr 58 ± 15 Indexes of CSF inflammationc
Male sex – no (%) 221 (47 %) Opening pressure (mm H2O) 42 ± 11
Duration of symptoms <24 h 225/461 (49 %) White blood cell count (/mm3) 2417 ± 5648
Pretreatment with antibiotics 58/459 (13 %) <1.000/mm3 130/454 (29 %)
Predisposing conditions 322/472 (68 %) Protein – g/L 4.7 ± 3.2
Otitis or sinusitis 218/471 (46 %) CSF: blood glucose ratio 0.13 ± 0.18
Immunocompromised 124/472 (26 %) Positive blood cultures 337/420 (80 %)
Symptoms and signs on presentationb Complications
Headache 363/427 (85 %) Cardiorespiratory failure 170/466 (36 %)
Neck stiffness 356/454 (78 %) Focal neurologic deficits 109/455 (24 %)
Epileptic seizures 33/454 (7 %) Epileptic seizures 69/460 (15 %)
Systolic blood pressure – mmHg 149 ± 29 Score on Glasgow Outcome Scale
Heart rate – beats/min 100 ± 21 1 – death 37 (8 %)
Body temperature – °C 38.8 ± 1.3 2 – vegetative state 1 (0.2 %)
Score on Glasgow Coma Scalec 11 ± 3 3 – severe disability 23 (5 %)
<8 indicating coma 63/472/87 %) 4 – moderate disability 90 (19 %)
Focal neurologic deficits 109/455 (25 %) 5 – good recovery 321 (68 %)
a Data are number/number evaluated (percentage), continuous data are mean ± SD. bSystolic blood pressure was evaluated in 469 patients, heart rate in 466,
temperature in 471. cCSF opening pressure was evaluated in 165 patients, CSF WBC count in 454 patients, CSF protein in 452, CSF blood: glucose ratio in 452
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mortality was not caused by differences in bacterial loads
or inflammatory response in Akt3-/- mice as compared
with wild-type mice. At 24 h post infection, we observed
no difference in bacterial loads in CSF, brain, blood, lung,
spleen and testis (Fig. 1d). Levels of TNF-α in brain hom-
ogenate levels were higher in Akt3-/- mice (p = 0.006), but
IL-1β, IL-6, IL-10, KC and MIP-2 levels were similar be-
tween Akt3-/- and wild-type mice (Fig. 1e). Histopatho-
logical examination showed higher histopathology scores
for parenchymal damage (infiltration) and vascular infil-
tration (large meningeal artery inflammation) in Akt3 -/-
mice as compared to wild-type mice; there were no differ-
ences in parenchymal damage (infarction, haemorrhage,
abscess), vascular infiltration (small parenchymal vessel in-
flammation) meningeal inflammation, ventriculitis, throm-
bosis, or hippocampal apoptosis between Akt3 -/- and
wild-type mice (Figs. 2 and 3).
AKT3 rs10157763 variant and risk factors for unfavourable
outcome
Having validated the role of Akt3 in pneumococcal men-
ingitis, we explored the associations between this poly-
morphism (rs10157763) and clinical features (Table 3).
Consistent with our animal data, we found no differ-
ences in CSF protein cytokine levels of IL-1β, IL-6 and
IL-10 between patients with risk or non-risk alleles at
the diagnostic lumbar puncture (Fig. 4). In contrast to
the mouse experiments, no differences in CSF TNF-α
concentration was observed between genotypes. Patients
with the risk genotype (AA: 9.9 %) had an increased risk
for seizures (OR 2.94, 95 % CI 1.11–7.80), less frequently
exhibited fever (OR 0.43, 95 % CI 0.21–0.84), and had
lower scores on the GCS score on admission (median 9
vs 11, p = 0.006) as compared with the non-risk genotypes
(GG and AG: 40.6 and 49.5 % respectively). In a multivari-
able regression analysis, including previously identified risk
factors for unfavourable outcome (age, CSF white blood
cell count < 1000/mm3, score on the GC, blood thrombo-
cyte count, immunocompromise, otitis media, and/or
sinusitis) [2, 9, 29], the predictive effect of rs10157763
remained robust (OR 3.6, 95 % CI 1.66–7.87; p = 0.001).
Discussion
In the first genome wide association study on outcome
in pneumococcal meningitis gene variants in AKT3,
DCTN4 and RAET1E were associated with unfavourable
outcome in adults with pneumococcal meningitis. As no
clinical cohort is available for validation [18], we explored
our findings in our pneumococcal meningitis mouse
model. The identified downregulation and increased mor-
tality during experimental meningitis confirmed a role of
Akt3 during pneumococcal meningitis, although the exact
mechanism remains unclear.
In pneumococcal meningitis, brain damage and un-
favourable outcome result from massive neutrophil re-
cruitment and inflammation of the brain, reflected by
CSF pleocytosis, seizures, and cerebrovascular complica-
tions [30, 31]. Patients with the AKT3 risk allele had a
higher level of disease severity, consisting of lower level
of consciousness, and a higher risk for epileptic seizures.
AKT3 is a critical signalling protein in the Phosphoinosi-
tide 3-kinase pathway involved in diverse cellular process
such as cell survival, growth, proliferation, metabolism
and migration [32]. Inhibition of AKT has been shown to
promote apoptosis in many cell types [33, 34].
AKT has been shown to be essential to induce neutrophil
extracellular traps, which are pro-inflammatory and
important to kill bacteria [35]. In a model of myelin-
oligodendrocyte glycoprotein–induced experimental auto-
immune encephalomyelitis (EAE), Akt3-/- mice were more
severely affected than wild-type mice [36]. Experiments
using bone marrow chimeras demonstrated that Akt3-/-
mice receiving Akt3-deficient bone marrow cells had ele-
vated clinical scores relative to control wild-type mice
reconstituted with wild-type cells, indicating that altered
function of both central nervous system (CNS) cells and
bone marrow-derived immune cells contributed to the
phenotype [36]. These experiments showed that Akt3-/-
mice have increased inflammatory cytokine expression in
Table 2 Novel SNPs associated with unfavorable outcome in patients with pneumococcal meningitis
Gene Chr Variation type dbSNIPID BP Alleles Allele frequency P BONF_P OR (+/− 95 CI)
Effectd Othere UF F
DCTN4a 5 Upstream gene variant rs6869603b 150142849 G A 0.07 0.01 2.4 × 10−05 1 5.6 (2.4–12.9)
DCTN4 5 F349L, F342L, F285L rs11954652b 150097883 G C 0.07 0.01 2.4 × 10−05 1 5.6 (2.4–12.9)
RAET1E 6 E89E, E53E rs3798763c 150211100 G A 0.37 0.23 9.4 × 10−05 1 1.9 (1.4–2.6)
RAET1E 6 R128H, R92H rs6925151c 150210723 G A 0.37 0.23 9.4 × 10−05 1 1.9 (1.4–2.6)
AKT3 1 Silent rs10157763 243995041 A G 0.40 0.26 9.9 × 10−05 1 1.9 (1.4–2.6)
BP denotes base pair, UF unfavourable outcome, F favourable outcome
a Variation within a regulatory area of this gene
b,c Markers in linkage disequilibrium (LD)
d Risk allele associated with unfavorable outcome
e Allele without risk
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spinal cord during acute EAE [36]. In our experiments,
Akt3-/- mice had similar bacterial outgrowth and mild host
inflammatory response as compared to wild-type mice. For
neuropathology, we only evaluated a relatively early time-
point (24 h) without antibiotic treatment in which gross
pathology usually do not present yet. As knockout mice
Fig. 1 dctn4 and akt3 mRNA expression levels and role of Akt3 in experimental pneumococcal meningitis. a Wild-type mice were infected with
1 × 104 colony-forming units (CFU) of S. pneumoniae serotype 3, strain 6303 via intracisternal inoculation. mRNA levels were assessed after 6 and
30 h in brain tissue (n = 6 control mice and 12 infected mice). b Kaplan-Meier survival of mice following intracisternal injection with 1 × 104 CFU
of S. pneumoniae serotype 3, strain 6303. Survival was monitored two to four times a day over a 48 h period and data analysed using Log-rank
test. c Clinical scores for each infected mouse group used in the survival study. Scores were compared using a nonlinear mixed effects model,
assuming exponential growth (y = β0 + e(β1x)). d Bacterial counts in organs and plasma during S. pneumoniae meningitis. e Selected cytokine/
chemokine levels in brain homogenates of infected mice. Each circle represents a single mouse and the bar indicates the group median
expression. Significance was determined using the non-parametric test Mann-Whitney U
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started to die after 24 h however, we were unable to post-
pone this time point without introducing selection bias in
our results. Nevertheless, Akt3-/- mice showed increased
parenchymal infiltration and artery inflammation as com-
pared to wild-type mice, suggesting an important role of
AKT3 in brain integrity and inflammation. In line, a plaus-
ible mechanism in which AKT3 is involved in meningitis is
by influencing the inflammatory response through influen-
cing apoptosis of inflammatory cells.
An alternative explanation for the poor prognosis
associated with AKT3 could be a decreased seizure
threshold. Enhanced activation of the mammalian target
of rapamycin (mTOR)-signalling cascade has been identi-
fied in focal malformations of cortical development
subtypes, which have been collectively referred to as
“mTORopathies.” Mutations in mTOR regulatory genes
such as AKT3 have been associated with epilepsy [37, 38].
Upstream and downstream molecules involved in serine/
threonine kinase AKT pathways, including Akt3, were
found to be involved in epilepsy pathophysiology [32]. In-
deed, patients with the risk genotype presented with a high
rate of epileptic seizures, but we did not observe a higher
seizure rate in our animal model. The animals however,
were checked every 4 h (24 h after inoculation) and we did
not perform a continuous (video) surveillance for seizures.
We previously described that community acquired bacterial
meningitis is complicated by seizures in 17 % of episodes
and seizures are associated with a high mortality rate
(41 %) [6]. Seizures have been associated with severe CNS
inflammation and structural CNS lesions, but it is unclear
whether the seizures are due to, or cause CNS damage [6].
The genetic variant rs10157763 in AKT3 has been pre-
viously associated with aggressive prostate carcinoma
and renal cell carcinoma [39]. rs10157763 variant has
been described to alter the transcriptional factor binding
sites (TFBS) for transcription factors that regulate AKT3
expression.
Genetic variants in DCTN4 and RAET1E were also
associated with functional outcome in pneumococcal
meningitis, but these findings will need to be validated.
DCTN4 is a component of the dynein-dependent motor
that moves autophagosomes along microtubules into
Fig. 2 Histopathology scores in S. pneumoniae-infected mouse brains. Histopathological changes in mice 24 h after intracisternal injection with
1 × 104 CFU of S. pneumoniae serotype 3, strain 6303. Data are represented as median. Statistical analysis was performed using Mann-Whitney U test. a
Parenchymal damage, b vascular infiltration, c meningeal infiltration, d ventriculitis, e thrombosis, f caspase-3 positive cells
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Fig. 3 Histopathology during experimental S. pneumoniae meningitis. a-e Representative haematoxylin and eosin and f caspase-3- stained
sections of a wild-type brain infected with 1 × 104 colony-forming units (CFU) of S. pneumoniae serotype 3, strain 6303 via intracisternal inoculation
(24 h post inoculation). a Red asterisks show parenchymal infiltration of neutrophils. Arrows indicate b inflammation of and destruction of meningeal
vessel, c parenchymal bleeding, d thrombosis in meningeal vessel, e apoptotic cell with pyknotic nucleus in the dentate gyrus of hippocampus and
f caspase-3 positive cells in the dentate gyrus of hippocampus
Table 3 Clinical characteristics and outcome per genotype in 396 white patients with community-acquired pneumococcal
meningitisa
Characteristic GG (n = 195) AG (n = 162) AA (n = 39) p-value recessive model
Age 58 ± 14 60 ± 13 56 ± 17
Gender 86 (44 %) 79 (49 %) 17 (44 %) 0.63
Glasgow Coma Scale Score 11 ± 3 11 ± 3 9 ± 3 0.006
Seizures on admission 12/188 (7 %) 10/158 (6 %) 6/36 (17 %) 0.024
Fever 168 (86 %) 123 (76 %) 26 (67 %) 0.019
Focal neurologic abnormalities 43 (22 %) 58 (36 %) 14 (36 %) 0.28
Leukocytes <1000 50 (26 %) 52 (32 %) 13 (36 %) 0.36
Respiratory failure 39/191 (21 %) 44/157 (29 %) 13 (33 %) 0.29
Mechanical ventilation 56/186 (30 %) 64/158 (41 %) 18/38 (47 %) 0.19
Seizures during admission 25/192 (14 %) 27/154 (18 %) 5/39 (13 %) 0.76
Focal neurologic deficit during admission 44/188 (23 %) 38/155 (24 %) 15/37 (41 %) 0.02
Unfavourable outcome 57/195 (29 %) 52/162 (32 %) 22/38 (58 %) 0.001
Death 12/195 (6 %) 13/162 (8 %) 4/38 (11 %) 0.43
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lysosomes for degradation as part of the autophagy
process - a highly conserved cellular quality control
mechanism to transport and degrade damaged proteins
and microbes [40, 41]. Exome sequencing of extreme
phenotypes previously has identified DCTN4 as a modi-
fier of chronic Pseudomonas aeruginosa infection in
patients with cystic fibrosis [42]. RAET1E is a major
histocompatibility complex class 1-like molecule and is a
functional ligand for an activating receptor expressed on
the surface of immune antigen-presenting cells such as
natural killer (NK) cells, CD8(+) T cells, and subsets of
CD4(+) T cells [43]. High levels of RAET1E expression
on antigen-presenting cells induces down-regulation of
NK cell activation by a regulatory T-cell subset [44]. NK
cells have been shown to be important for the protection
against various microbial pathogens, including S. pneu-
moniae [45], and have shown to contribute to mortality
in experimental pneumococcal pneumonia [46]. We did
not further study these genes in our animal model as we
did not find the genes differentially expressed during
meningitis, although this does not completely negate a
role in the pathophysiology of pneumococcal meningitis.
Our study has several limitations. First, captured varia-
tions with the Human Exome BeadChip are mainly re-
stricted to protein coding regions and used as stand-alone
array for identification of the causal variant can be
difficult.
Second, some selection bias was possibly introduced
since DNA was not available for a considerable proportion
of patients (34 %), particularly those with more severe
disease. Inclusion of patients with less severe disease will
decrease study power to detect genetic variants associated
with outcome, resulting in more type II errors (accepting
the null hypothesis when it is false). The nationwide de-
sign allowed us to detect this selection bias. Third, we
could not validate our findings of the genetic association
study in a different cohort. The candidate SNPs were asso-
ciated with unfavourable outcome with a p-value lower
than 1 × 10−4, indicating that findings could still be a type
I error. However, no cohorts are currently available for
outcome in adult pneumococcal meningitis to validate our
results. Therefore, we validated one genetic variant that
was upregulated during meningitis in our adult mouse
pneumococcal meningitis model [23]. Fourth, to further
contribute to elucidate the underlying mechanism(s) on
meningitis-associated brain pathology, information regar-
ding tissue protein expression of Akt3 and TNF-α, phe-
notypical characterization of the cell infiltrate and
experiments using TNF- α blocking agents should be
assessed in further experiments.
Conclusions
In conclusion, we identified gene variants in AKT3,
DCTN4 and RAET1E to be associated with unfavourable
outcome in adults with pneumococcal meningitis. We
validated the role of Akt3 in our experimental pneumo-
coccal meningitis model. Our study show that a GWAS
approach in pneumococcal meningitis provides new
Fig. 4 CSF protein cytokine levels between patients with risk or non-risk alleles. a-d The cytokines IL-6, TNF-α, IL-1β and IL-10 were determined in
pneumococcal meningitis patient CSF samples collected from the diagnostic lumbar puncture. Data are represented as median of individual
patients grouped on their AKT3 rs10157763 genotypes AA, AG and GG. Statistical analysis was performed using Mann-Whitney U test
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insights in the pathophysiology of pneumococcal disease
and may provide new leads for the development of
adjunctive therapies.
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